Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Togashi

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2011
[Retinal-blood barrier]Yu Togashi, Yasuo Terauchi
Endocrine Journal|March 8, 2008
Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patientsTomoyuki Iwasaki, Yu Togashi, Yasuo Terauchi
Internal Medicine (Tokyo, Japan)|June 19, 2010
Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover studyKazutaka Aoki, Tomonori Muraoka, Yuzuru Ito, et al.
Endocrine Journal|December 22, 2012
Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic menKazutaka Aoki, Hiroshi Kamiyama, Kiyomi Masuda, et al.
Endocrine Journal|June 4, 2010
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic menKazutaka Aoki, Kiyomi Masuda, Takashi Miyazaki, et al.
Endocrine Journal|June 4, 2010
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy menKazutaka Aoki, Takashi Miyazaki, Jo Nagakura, et al.
European Journal of Pharmacology|January 3, 2016
Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse modelKazuki Orime, Jun Shirakawa, Yu Togashi, et al.
Diabetes Research and Clinical Practice|January 22, 2008
Neither the presence of metabolic syndrome as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular or macrovascular complications in Japanese patients with type 2 diabetesTomoyuki Iwasaki, Yu Togashi, Kenji Ohshige, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 18, 2017
Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat dietKazuki Tajima, Jun Shirakawa, Tomoko Okuyama, et al.
Scientific Reports|June 25, 2017
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906Kazuki Tajima, Jun Shirakawa, Yu Togashi, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2011
[Retinal-blood barrier]Yu Togashi, Yasuo Terauchi
Endocrine Journal|March 8, 2008
Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patientsTomoyuki Iwasaki, Yu Togashi, Yasuo Terauchi
Internal Medicine (Tokyo, Japan)|June 19, 2010
Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover studyKazutaka Aoki, Tomonori Muraoka, Yuzuru Ito, et al.
Endocrine Journal|December 22, 2012
Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic menKazutaka Aoki, Hiroshi Kamiyama, Kiyomi Masuda, et al.
Endocrine Journal|June 4, 2010
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic menKazutaka Aoki, Kiyomi Masuda, Takashi Miyazaki, et al.
Endocrine Journal|June 4, 2010
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy menKazutaka Aoki, Takashi Miyazaki, Jo Nagakura, et al.
European Journal of Pharmacology|January 3, 2016
Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse modelKazuki Orime, Jun Shirakawa, Yu Togashi, et al.
Diabetes Research and Clinical Practice|January 22, 2008
Neither the presence of metabolic syndrome as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular or macrovascular complications in Japanese patients with type 2 diabetesTomoyuki Iwasaki, Yu Togashi, Kenji Ohshige, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 18, 2017
Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat dietKazuki Tajima, Jun Shirakawa, Tomoko Okuyama, et al.
Scientific Reports|June 25, 2017
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906Kazuki Tajima, Jun Shirakawa, Yu Togashi, et al.
Pageof 5